Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation

doi:10.4254/wjh.v6.i5.315

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 5

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6327)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

651

WORD

351

HTML

3838

Tables (1-3)

343

Sum=5183

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

622

Download

522

Sum=1144

May 27, 2014 (publication date) through Apr 3, 2025

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. May 27, 2014; 6(5): 315-325
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.315

Table 3 Prophylactic schemes against hepatitis B virus recurrence after liver and renal transplantation when grafts are from hepatitis B virus positive donors

	Donor	Recipient	Prophylaxis
Liver transplantation	Anti-HBc positive	HBsAg positive	HBIG plus NA
		HBsAg negative	No prophylaxis
		Anti-HBc positive
		Anti-HBs positive
		Anti-HBc negative	Long term lamivudine
		Anti-HBs negative	Long term lamivudine
	HBsAg positive	Anti-HBc positive	HBIG plus NA
Kidney transplantation	Anti-HBc positive	HBsAg negative	No prophylaxis
	Anti-HBc positive	HBsAg negative	Treatment when HBV DNA increases
	HBsAg positive	HBsAg positive	HBIG plus lamivudine
	(HBV DNA negative)	HBsAg negative	Long term lamivudine
	(HBV DNA negative)	(HBV DNA) negative	Long term lamivudine

HBV: Hepatitis B virus; NA: Nucleos(t)ide analog; HBIG: Hepatitis virus immunoglobulin.

Citation: Pipili C, Cholongitas E. Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation. World J Hepatol 2014; 6(5): 315-325
URL: https://www.wjgnet.com/1948-5182/full/v6/i5/315.htm
DOI: https://dx.doi.org/10.4254/wjh.v6.i5.315